CureSight, a digital treatment device, was noninferior to eye patching for pediatric amblyopia in a pivotal clinical study, NovaSight announced in a press release.
The multicenter randomized controlled trial compared the eye tracking-based device with patching in 103 subjects between the ages of 4 and 9 years. The device, which trains the visual system to use both eyes simultaneously, was noninferior to the current standard of care.
In addition, participants treated with CureSight experienced a greater improvement in best corrected visual acuity after 16 weeks. No serious adverse events were